|
Diabetes, Vol 45, Issue 12 1734-1743, Copyright © 1996 by American Diabetes Association
Increased hexosamine availability similarly impairs the action of insulin and IGF-1 on glucose disposal
M Hawkins, N Barzilai, W Chen, I Angelov, M Hu, P Cohen and L Rossetti
Division of Endocrinology, Albert Einstein College of Medicine, Bronx, New York 10461, USA.
Prolonged glucosamine (GlcN) infusion increases the skeletal muscle
hexosamine concentration and induces peripheral insulin resistance in
conscious rats. IGF-1 and insulin share common steps in signal
transduction, and the action of IGF-1 on carbohydrate metabolism is
preserved in certain insulin-resistant states. In our study, we attempted
to delineate whether increased GlcN availability also impairs the effects
of IGF-1 on glucose uptake (Rd), glycolysis, and glycogen synthesis. We
performed euglycemic IGF-1 (5 and 15 microg x kg(-1) x min(-1)) and insulin
(3 and 18 mU mg x kg(-1) x min(-1)) clamp studies at 0-2 h and 5-7 h in
conscious rats (n = 44) during saline or GlcN infusions. GlcN infusion
raised plasma GlcN levels to approximately 2.0 mmol/l and skeletal muscle
uridinediphospho-n-acetylglucosamine to 80-150 nmol/g (approximately three-
to fivefold over basal). During physiological hyperinsulinemia (3 mU x
kg(-1) x min(-1), plasma insulin approximately 50 microU/ml), GlcN infusion
caused comparable decreases in Rd (15.7 +/- 1.0 [5-7 h] vs. 21.7 +/- 2.3
[0-2 h] mg x kg(-1) x min(-1); P < 0.01) and glycogen synthesis (5.4 +/-
0.5 [5-7 h] vs. 10.4 +/- 1.9 [0-2 h] mg x kg(-1) x min(-1); P < 0.005).
Furthermore, GlcN markedly decreased Rd by 7.8 +/- 1.2 mg x kg(-1) x
min(-1) (18.7 +/- 0.7 [5-7 h] vs. 26.5 +/- 1.3 [0-2 h] mg x kg(-1) x
min(-1); P < 0.001 vs. control) during IGF-1 (5 microg x kg(-1) x
min(-1)) clamp studies. This decline was associated with a 26% decrease in
the steady-state concentration of skeletal muscle Glc-6-P (286 +/- 45 vs.
386 +/- 36 nmol/g; P < 0.01) and was primarily caused by impaired
glycogen synthesis (6.7 +/- 0.5 [5-7 h] vs. 13.9 +/- 0.9 [0-2 h] mg x
kg(-1) x min(-1); P < 0.005). The effects of GlcN infusion on glucose
disposal (percentage decrease in Rd) were correlated (r2 = 0.803; P <
0.01) with the skeletal muscle concentration of UDP-GlcNAc. To investigate
whether IGF-1 can overcome GlcN-induced insulin resistance, GlcN and
insulin (18 mU x kg(-1) x min(-1)) were infused for 7 h during euglycemic
clamps, and IGF-1 (15 microg x kg(-1) x min(-1)) was superimposed during
the final 2 h. GlcN infusion induced severe impairment of insulin action on
Rd (39.4 +/- 3.2 [4-5 h] vs. 49.8 +/- 3.6 [1-2 h] mg x kg(-1) x min(-1); P
< 0.05), which the addition of IGF-1 failed to improve (35.9 +/- 2.3
[6-7 h] vs. 39.4 +/- 3.2 [4-5 h] mg x kg(-1) x min(-1); P > 0.1). In
summary, GlcN induced severe resistance to the actions of both insulin and
IGF-1 on glucose uptake and glycogen synthesis, and IGF-1 was unable to
overcome GlcN-induced insulin resistance. Thus, it is likely that GlcN
causes peripheral insulin resistance acting at a site common to both IGF-1
and insulin signaling pathways.

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
D. C. Love and J. A. Hanover
The Hexosamine Signaling Pathway: Deciphering the "O-GlcNAc Code"
Sci. Signal.,
November 29, 2005;
2005(312):
re13 - re13.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. D. Lazarus, M. D. Roos, and J. A. Hanover
Mutational Analysis of the Catalytic Domain of O-Linked N-Acetylglucosaminyl Transferase
J. Biol. Chem.,
October 21, 2005;
280(42):
35537 - 35544.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Parker, R. Taylor, D. Jones, and D. McClain
Hyperglycemia and Inhibition of Glycogen Synthase in Streptozotocin-treated Mice: ROLE OF O-LINKED N-ACETYLGLUCOSAMINE
J. Biol. Chem.,
May 14, 2004;
279(20):
20636 - 20642.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. A. Scroggie, A. Albright, and M. D. Harris
The Effect of Glucosamine-Chondroitin Supplementation on Glycosylated Hemoglobin Levels in Patients With Type 2 Diabetes Mellitus: A Placebo-Controlled, Double-blinded, Randomized Clinical Trial
Arch Intern Med,
July 14, 2003;
163(13):
1587 - 1590.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Sakai and D. R. Clemmons
Glucosamine Induces Resistance to Insulin-Like Growth Factor I (IGF-I) and Insulin in Hep G2 Cell Cultures: Biological Significance of IGF-I/Insulin Hybrid Receptors
Endocrinology,
June 1, 2003;
144(6):
2388 - 2395.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. G. Spiro
Protein glycosylation: nature, distribution, enzymatic formation, and disease implications of glycopeptide bonds
Glycobiology,
April 1, 2002;
12(4):
43R - 56R.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Pratipanawatr, K. Cusi, P. Ngo, W. Pratipanawatr, L. J. Mandarino, and R. A. DeFronzo
Normalization of Plasma Glucose Concentration by Insulin Therapy Improves Insulin-Stimulated Glycogen Synthesis in Type 2 Diabetes
Diabetes,
February 1, 2002;
51(2):
462 - 468.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. A. HANOVER
Glycan-dependent signaling: O-linked N-acetylglucosamine
FASEB J,
September 1, 2001;
15(11):
1865 - 1876.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Rossetti
Perspective: Hexosamines and Nutrient Sensing
Endocrinology,
June 1, 2000;
141(6):
1922 - 1925.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.-B. Book and A. Dunaif
Selective Insulin Resistance in the Polycystic Ovary Syndrome
J. Clin. Endocrinol. Metab.,
September 1, 1999;
84(9):
3110 - 3116.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
T. P. Ciaraldi, L. Carter, S. Nikoulina, S. Mudaliar, D. A. McClain, and R. R. Henry
Glucosamine Regulation of Glucose Metabolism in Cultured Human Skeletal Muscle Cells: Divergent Effects on Glucose Transport/Phosphorylation and Glycogen Synthase in Non-Diabetic and Type 2 Diabetic Subjects
Endocrinology,
September 1, 1999;
140(9):
3971 - 3980.
[Abstract]
[Full Text]
|
 |
|

|
 |

|
 |
 
K. M. Kelley, T. R. Johnson, J. Ilan, and R. W. Moskowitz
Glucose regulation of the IGF response system in chondrocytes: induction of an IGF-I-resistant state
Am J Physiol Regulatory Integrative Comp Physiol,
April 1, 1999;
276(4):
R1164 - R1171.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Hawkins, I. Angelov, R. Liu, N. Barzilai, and L. Rossetti
The Tissue Concentration of UDP-N-acetylglucosamine Modulates the Stimulatory Effect of Insulin on Skeletal Muscle Glucose Uptake
J. Biol. Chem.,
February 21, 1997;
272(8):
4889 - 4895.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 1996 by the American Diabetes Association.
|
|
| |
|